Huang Ye, Choo Charlene, Hancock Shelley, Ciulla Thomas A, Wykoff Charles C, Shantha Jessica G, Yeh Steven
Department of Ophthalmology and Visual Sciences, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA.
F.I. Proctor Foundation, University of California, San Francisco, CA, USA.
J Vitreoretin Dis. 2024 Apr 25;8(4):401-409. doi: 10.1177/24741264241246314. eCollection 2024 Jul-Aug.
To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. A synthesis of the literature was performed. In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.
评估文献中聚焦于脉络膜上腔给药治疗非感染性葡萄膜炎及其他后段疾病的临床试验。进行了文献综述。2021年，用于治疗葡萄膜炎性黄斑水肿（ME）的皮质类固醇递送系统——脉络膜上腔曲安奈德被美国食品药品监督管理局批准。该给药系统使用基于微针的装置靶向脉络膜上腔，具有良好的药代动力学特征。脉络膜上腔给药的研究性疗法也已在其他后段疾病的临床试验中进行评估，包括糖尿病性ME、视网膜静脉阻塞、年龄相关性黄斑变性和脉络膜黑色素瘤。近期的III期临床试验已表明脉络膜上腔注射皮质类固醇治疗葡萄膜炎性ME的安全性和有效性。多个项目也在研究这种给药方式用于许多其他视网膜和脉络膜疾病。
